Key Takeaways
- The FcRn inhibitor Imaavy (nipocalimab) was approved by the FDA for generalized myasthenia gravis, where it will compete against two similar drugs.
Johnson & Johnson’s Imaavy (nipocalimab) was approved by the US Food and Drug Administration for generalized myasthenia gravis (gMG), but...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?